Tevaarwerk, A. ., Wilding, G. ., Eickhoff, J. ., Chappell, R. ., Sidor, C. ., Arnott, J. ., … Liu, G. . (2012). Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Investigational New Drugs, 30(3), 1039-45. https://doi.org/10.1007/s10637-010-9629-6 (Original work published 2012)
G Wilding
First name:
G
Last name:
Wilding